Company Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson’s Real Answer To Imminent Decline In Sales Of Top-Selling Drug

[at Seeking Alpha] – Remicade, one of the most potent drugs available on the market for treating arthritis, is currently Johnson & Johnson’s ( JNJ ) most important product with regards to sales . . . → Read More: Company Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson’s Real Answer To Imminent Decline In Sales Of Top-Selling Drug Similar posts: Merck & Co. Inc. (NYSE:MRK) – Germany’s Merck looks for deals to lift U.S. drug sales Market Update on Biogen Idec Inc. (NASDAQ:BIIB) – Biogen’s new MS drug tops sales expectations, earnings rise Commodities lead decline, US retail sales on tap